CDR111 / CDR-Life, Boehringer Ingelheim - LARVOL DELTA

Boehringer Ingelheim and CDR-Life have entered into a global licensing agreement to advance the development of CDR111, an antibody-based molecule designed to address autoimmune diseases. (GeneOnline) - "The agreement grants Boehringer Ingelheim exclusive worldwide rights to develop and commercialize CDR111....Under the terms of the deal, CDR-Life will receive an upfront payment along with milestone payments based on development progress and sales achievements. Additionally, royalties on future sales are included in the agreement. Both companies have expressed their commitment to advancing research in this field through this partnership."

Licensing / partnership • Immunology

CDR111 is a novel CD19 and BCMA dual-targeting T cell engager (TCE) for the treatment of severe and refractory autoimmune diseases (ACR Convergence 2025) - "CDR111 demonstrates a differentiated approach to treating autoimmune patients. While showing peripheral B cell depletion with controlled cytokine release, it achieves potent plasma cell eradication in lymphoid organs (bone marrow and spleen). CDR111 holds the potential for a true B cell reset, resulting in durable treatment-free disease remission in patients with severe or refractory autoimmune diseases like SLE and rheumatoid arthritis."

IO biomarker • Hematological Malignancies • Immunology • Inflammatory Arthritis • Lupus • Rheumatoid Arthritis • Rheumatology • Systemic Lupus Erythematosus • CD34 • NECTIN1